Korean health watchdog launches Post-Approval safety check for rare blood disorder drug
NCT ID NCT07457151
Summary
This study aims to monitor the safety and effectiveness of Danicopan, a medication for a rare blood disease called PNH, in real-world Korean medical settings. It will follow 8 patients already receiving Danicopan alongside their standard treatment to check for side effects and see if it helps improve their blood counts and reduce fatigue. The goal is to confirm the drug's real-world performance after its initial approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.